GLP-1 weight loss drugs like semaglutide and tirzepatide show strong short-term benefits in reducing obesity and improving overall metabolic health alongside lifestyle changes.

Over time, the drugs could potentially lower morbidity, support return-to-work outcomes, and reshape insurance assumptions around chronic disease and mortality risk.

Here, we present our 20-year mortality reduction scenario forecasts across countries, reflecting the possible long-term impact of widespread GLP-1 adoption and metabolic health changes more broadly.

Speakers:

Dr Adam Strange, Research Scientist, Swiss Re

Dr Debbie Smith, Chief Medical Officer, Swiss Re

Chair: Nicky Draper, IFoA Honorary Fellow